Estimated Cost Impact on Public Healthcare System from Adding Risdiplam on List of Subsidised Drugs

Ong Hua Han inquired how the Ministry of Health's Drug Advisory Committee estimated the annual cost impact of listing risdiplam on the subsidised drugs list to be $5 million to $10 million in the first five years.
Ong Ye Kung directed the questioner to a prior official reply given on 2 July 2024 regarding the annual cost of risdiplam for spinal muscular atrophy treatment and the Drug Advisory Committee's decisions.
The debate summary indicates that the specific cost estimation methodology was not reiterated in this session but referenced to an earlier documented parliamentary response.

Ong Hua Han inquired how the Ministry of Health's Drug Advisory Committee estimated the annual cost impact of listing risdiplam on the subsidised drugs list to be $5 million to $10 million in the first five years.
Ong Ye Kung directed the questioner to a prior official reply given on 2 July 2024 regarding the annual cost of risdiplam for spinal muscular atrophy treatment and the Drug Advisory Committee's decisions.
The debate summary indicates that the specific cost estimation methodology was not reiterated in this session but referenced to an earlier documented parliamentary response.

Ong Hua Han inquired how the Ministry of Health's Drug Advisory Committee estimated the annual cost impact of listing risdiplam on the subsidised drugs list to be $5 million to $10 million in the first five years.
Ong Ye Kung directed the questioner to a prior official reply given on 2 July 2024 regarding the annual cost of risdiplam for spinal muscular atrophy treatment and the Drug Advisory Committee's decisions.
The debate summary indicates that the specific cost estimation methodology was not reiterated in this session but referenced to an earlier documented parliamentary response.

Ong Hua Han inquired how the Ministry of Health's Drug Advisory Committee estimated the annual cost impact of listing risdiplam on the subsidised drugs list to be $5 million to $10 million in the first five years.
Ong Ye Kung directed the questioner to a prior official reply given on 2 July 2024 regarding the annual cost of risdiplam for spinal muscular atrophy treatment and the Drug Advisory Committee's decisions.
The debate summary indicates that the specific cost estimation methodology was not reiterated in this session but referenced to an earlier documented parliamentary response.

Summary